This paper presents a white-paper overview of a need-based cancer drug treatment program, addressing the major challenges faced by cancer patients from diagnosis through post-treatment recovery. It explores the economic burden of cancer illness — including lost productivity, caregiver costs, and phase-specific treatment expenses — as well as the special psychosocial and informational needs of cancer patients. The paper outlines the key steps in the treatment process, from diagnosis and treatment decision-making to post-treatment care and evaluation, and describes the specific benefits offered by the proposed drug program, including online enrollment and coordinated rehabilitative care.
Cancer is among the most fatal diseases known to medicine, involving the abnormal growth and division of body cells that results in tumor formation affecting one or many parts of the body. Because cancer cells can invade neighboring tissues, early detection and careful treatment are deemed absolutely necessary. Treatment is not only costly but typically involves multi-stage radiation therapies (Castro, 2001). More than 13% of human deaths worldwide are caused by cancer-related diseases, and because treatment is expensive across the globe, new drug development also requires multi-million-dollar research and development investments.
Rigorous laboratory tests are conducted before cancer drugs are approved for administration to patients. The drug development process involves both preclinical and translational work. This paper presents the major issues surrounding cancer drug development, including economic issues, the special needs of the specific population being served, the process and steps involved in the program, and the benefits of the drug treatment program.
Thesis Statement: New drug development for cancer requires multi-million-dollar R&D investments, while patient costs for obtaining cancer treatment are also high and include difficult, multi-stage treatments. To help address this, our company has developed a new cancer treatment drug to be administered through a need-based treatment program. This program will address the economic challenges of patients requiring cancer treatment, serve the special needs of the intervention population, and provide specific health benefits to participant patients.
The burden of illness from cancer has been documented extensively in intervention research. Yabroff et al. (2004) cited data from the 2000 National Health Survey, in which data from 1,823 cancer survivors were tracked. Results showed that the burden of illness from cancer was significant across many life areas, including overall health status, days lost from work, and health utility lost.
Patients lose productivity because they are rendered immobile by cancer treatment. Days lost from work were reported to be as many as 65 out of 260 working days. Self-rated health status among cancer patients was also lower compared to non-cancer patients. Across all cancer types — prostate, colorectal, lung, and breast — worse health outcomes lead to increased health expenditures. Additional use of health services further limits the mobility of cancer patients and reduces their economic prospects due to the demands of continued treatment.
Caregiver burden is another significant economic factor. Loss of work on the part of caregivers represents an economic loss, and continued absence from work is often required to care for cancer patients. The cost of illness is both direct and indirect, encompassing phase-specific treatment costs as well as long-term economic expenses. The most affected group of cancer patients is typically those who have received a recent diagnosis, as new diagnoses significantly reduce the number of working days available to patients and their caregivers.
Cancer patients have special health needs that must be addressed at regular intervals. McIllmurray et al. (2001) reported that the health needs of cancer patients differ substantially from those associated with other ailments. Patients require assistance from healthcare professionals as well as clear information regarding their recovery and ongoing health. A support network consisting of friends, family, and social acquaintances is also essential.
Among the most significant special needs is identity crisis management: patients frequently experience depression phases in which they search for a sense of self in the wake of their diagnosis. Emotional and spiritual support is also sought by cancer patients, though it is often underreported. Many researchers have established that health is an outcome of psychological and social variables, and social intervention events have been shown to help build the confidence and improve the health outcomes of cancer patients.
"Diagnosis, treatment decisions, and post-treatment care"
"Online enrollment, Medi-Cal benefits, and coordinated care"
Cancer is a disease that involves malfunction of cell growth and division in the body. The abnormal division and growth of cells results in tumor development in the patient. The economic issues involved in cancer treatment are numerous, with reduced mobility and loss of work being the most immediate consequences. Patients are frequently unable to maintain regular employment during treatment. Special health needs are also significant for cancer patients, with the most important being access to accurate information from physicians and access to psychological and social support. The developed drug is aimed at intervening particularly for aging populations, providing a targeted post-treatment recovery solution within a need-based program framework.
You’re 62% through this paper. Sign up to read the remaining 2 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.